Bradley 5 Charitable Fund Inc is a non-for-profit organization, 501 (C3) dedicated to finding a better treatment, understanding and providing funds for research for DVT Deep Vein Thrombosis. (Blood clots)
Change the views and current treatment for DVT. Taking charge of future studies in the field of blood coagulation. With the advancements in third generation blood thinning products, we as a society have became complacent in looking for a cure. The cure will hopefully be discovered from within institutions who study genetics. Not only will genetic research find the the answers to blood coagulation issues, but hopefully medical discoveries in other major diseases.
History/Origin
Bradley Hollar was 26 years old, married, with a 11 month old daughter working for a major pharmaceutical company in the Midwest when his life tragically ended unexpectedly. On February 27th, 2013, Bradley passed away instantly in his home. Weeks later the family was informed that his cause of death was that he had developed a blood clot that settled in his lungs. Upon autopsy results and pharmacology testing, it was discovered that Bradley suffered from a rare blood clotting disorder. The disorder is called Factor Five Leiden Mutation which is a genetic condition. In response to these finding, the family was advised that this genetic mutation is passed on through generations. Immediate testing found that Bradley’s only daughter as well as other family members, possesses the same genetic signature. After reviewing previous deaths of family members’, it was discovered that this genetic mutation may well have been the cause of other deaths. The only way that this discovery was made, is the direct result of Bradley’s death. His life although cut short, was not in vain. Within the first two years of his association with the pharmaceutical company, he was able to advance his career to the top of the sales field. Most long term or seasoned sales associates never obtain the prestigious honor of being at the top of the team and earning the President Club jacket. Within his first two years, Bradley obtained that honor. He was the youngest person in his organization to achieve that honor. Bradley possessed an extraordinary personality that became his trademark in making a difference with anyone he came into contact with. Although his family and career guided him, his faith was always at the forefront of Bradley’s decisions on his very short journey of life. He had accomplished achievements that were far beyond his time. His death may have been the very factor that has and will continue to save the lives of not only his family but of countless others who are affected by this rare, genetic condition. This fact alone is one of many reasons why the organization is eager to ignite the industry in testing, education to benefit others in the future. Factor V Leiden Factor V Leiden thrombophilia is an inherited disorder of blood clotting. Factor V Leiden is the name of a specific gene mutation that results in thrombophilia, which is an increased tendency to form abnormal blood clots that can block blood vessels. People with factor V Leiden thrombophilia have a higher than average risk of developing a type of blood clot called a deep venous thrombosis (DVT). DVTs occur most often in the legs, although they can also occur in other parts of the body, including the brain, eyes, liver, and kidneys. Factor V Leiden thrombophilia also increases the risk that clots will break away from their original site and travel through the bloodstream. These clots can lodge in the lungs, where they are known as pulmonary emboli. Although factor V Leiden thrombophilia increases the risk of blood clots, only about 10 percent of individuals with the factor V Leiden mutation ever develop abnormal clots. The factor V Leiden mutation is associated with a slightly increased risk of pregnancy loss (miscarriage). Women with this mutation are two to three times more likely to have multiple (recurrent) miscarriages or a pregnancy loss during the second or third trimester. Some research suggests that the factor V Leiden mutation may also increase the risk of other complications during pregnancy, including pregnancy-induced high blood pressure (preeclampsia), slow fetal growth, and early separation of the placenta from the uterine wall (placental abruption). However, the association between the factor V Leiden mutation and these complications has not been confirmed. Most women with factor V Leiden thrombophilia have normal pregnancies.
We stand at the doorsteps of the next generation in research, but we need your help. Any contribution can make a difference in research. Four generations that possess a genetic mutation called Leiden factor 5, Your gift matters,,
With several national organizations, universities, and hospitals already engaged in the study of this condition, continued funding is needed to bring this condition at the forefront for medical professionals nationwide in order to increase studies and trial efforts. The Bradley5 Organization believes that known conditions of this disease are similar in treatment as other known rare diseases currently affecting the blood. In the US, somewhere between 350,000-600,000 people will form a blood clot of some type each year. Treatments are already available for this disorder. Advancements in technology and research have been accomplished. The foundation wishes to further these efforts with safe medicines, early detection, alternative treatments, as well as a cure. As a society of acceptance, we have become complacent in the ongoing research and have accepted current treatment for DVT, and other blood clotting disorders. The pharmaceutical industry has developed treatments for DVT and is currently in the third generation of blood thinning products. While some of these medicines detour the blood clotting factors, they also possess high risk. Most of these products pose the risk of death. The secondary piece of the organizations funding will be to offer scholarships to students who continue their path of education by enrolling in an accredited college (private or public) who are pursuing degrees in the studies of human medicine, pharmacy, clinical research or other fields associated with the practice of medicine. Scholarships will also be awarded in the fields of marketing or business when the student’s pursuit includes medical devices or pharmaceuticals. The organization is also charged with preparing our future students to be able to enter the field of hematology, research, and genetic studies which affects many citizens of The United States.
Board of Directors
Dr. Lawrence Curry DO
Dr. Walter C Anglemeyer DO
Jim Sumpter Nappanee EMS
Christopher Walter Walter Law Office
Jack Lengacher Jr. J&N Stone
James F Shea
In January 2024 the charitable fund received a generous donation to create a fellowship program at Notre Dame's College of Science in honor of Bradley Hollar. The fellowship will offer research, specific to the field of Blood clotting research. We are honored and humbled to be a recipient of the fund. According to Notre Dame, this program will last forever, and we are certain that Science will someday be able to find a cure for Leiden Factor Five or at least a better treatment. Thank you, Jim Shea, for your generous support during our entire journey.
Your generous gift will help us fund our mission to help those in need. Together, we can make a difference.